FDA Purple Book · Reference family
romosozumab-aqqg (Evenity)
romosozumab-aqqg is an FDA-licensed reference biologic from Amgen Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2019
Reference approved
Reference product
351(a)BLA 761062
Evenity romosozumab-aqqg
Amgen Inc.
- Approved
- Apr 09, 2019
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for romosozumab-aqqg, in chronological order.
Reference approval
Approval date of the reference romosozumab-aqqg product.
7 yr 3 mo ago
Frequently asked questions
Are there biosimilars approved for romosozumab-aqqg (Evenity)?
No 351(k) biosimilars or interchangeable biosimilars referencing romosozumab-aqqg are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.